Fluid and Imaging Biomarkers in Lecanemab Therapy for Early Alzheimer’s Disease: Current Evidence, ARIA Risk Prediction, and Treatment Monitoring
Background/Objectives: Lecanemab, a humanized anti-amyloid-β protofibril antibody, achieves substantial amyloid clearance and modest slowing of clinical decline in early Alzheimer’s disease (AD). Amyloid-related imaging abnormalities (ARIA) represent the most clinically important safety concern, yet no fluid biomarker...